Author
Listed:
- John D. Strickley
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School
University of Louisville
University of Louisville)
- Jonathan L. Messerschmidt
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School)
- Mary E. Awad
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School)
- Tiancheng Li
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School)
- Tatsuya Hasegawa
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School)
- Dat Thinh Ha
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School
University of Louisville
University of Louisville)
- Henry W. Nabeta
(University of Louisville
University of Louisville)
- Paul A. Bevins
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School
University of Louisville
University of Louisville)
- Kenneth H. Ngo
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School)
- Maryam M. Asgari
(Massachusetts General Hospital and Harvard Medical School)
- Rosalynn M. Nazarian
(Massachusetts General Hospital and Harvard Medical School)
- Victor A. Neel
(Massachusetts General Hospital and Harvard Medical School)
- Alfred Bennett Jenson
(University of Louisville)
- Joongho Joh
(University of Louisville
University of Louisville
University of Louisville)
- Shadmehr Demehri
(Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School
Massachusetts General Hospital and Harvard Medical School)
Abstract
Immunosuppression increases the risk of cancers that are associated with viral infection1. In particular, the risk of squamous cell carcinoma of the skin—which has been associated with beta human papillomavirus (β-HPV) infection—is increased by more than 100-fold in immunosuppressed patients2–4. Previous studies have not established a causative role for HPVs in driving the development of skin cancer. Here we show that T cell immunity against commensal papillomaviruses suppresses skin cancer in immunocompetent hosts, and the loss of this immunity—rather than the oncogenic effect of HPVs—causes the markedly increased risk of skin cancer in immunosuppressed patients. To investigate the effects of papillomavirus on carcinogen-driven skin cancer, we colonized several strains of immunocompetent mice with mouse papillomavirus type 1 (MmuPV1)5. Mice with natural immunity against MmuPV1 after colonization and acquired immunity through the transfer of T cells from immune mice or by MmuPV1 vaccination were protected against skin carcinogenesis induced by chemicals or by ultraviolet radiation in a manner dependent on CD8+ T cells. RNA and DNA in situ hybridization probes for 25 commensal β-HPVs revealed a significant reduction in viral activity and load in human skin cancer compared with the adjacent healthy skin, suggesting a strong immune selection against virus-positive malignant cells. Consistently, E7 peptides from β-HPVs activated CD8+ T cells from unaffected human skin. Our findings reveal a beneficial role for commensal viruses and establish a foundation for immune-based approaches that could block the development of skin cancer by boosting immunity against the commensal HPVs present in all of our skin.
Suggested Citation
John D. Strickley & Jonathan L. Messerschmidt & Mary E. Awad & Tiancheng Li & Tatsuya Hasegawa & Dat Thinh Ha & Henry W. Nabeta & Paul A. Bevins & Kenneth H. Ngo & Maryam M. Asgari & Rosalynn M. Nazar, 2019.
"Immunity to commensal papillomaviruses protects against skin cancer,"
Nature, Nature, vol. 575(7783), pages 519-522, November.
Handle:
RePEc:nat:nature:v:575:y:2019:i:7783:d:10.1038_s41586-019-1719-9
DOI: 10.1038/s41586-019-1719-9
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:575:y:2019:i:7783:d:10.1038_s41586-019-1719-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.